Abstract dark blue gradient glow on a solid black background.
Abstract dark blue gradient glow on a solid black background.

Clinical Trials & Expanded Access Policy

Our Research in Action

Every breakthrough starts with a study. Learn about our clinical trials and how to participate.

Phase 3 RESTORE Study

Chronic Spinal Cord Injury

NVG-291: A Phase 3 Clinical Trial of an Investigational Neuroreparative Peptide

A multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating NVG-291 for the treatment of individuals living with chronic spinal cord injury.

U.S. and Canada
More Information at Clinicaltrials.gov

Expanded Access Policy

NervGen has initiated an Expanded Access Policy to allow treatment use of NVG-291 for those individuals with spinal cord injury who have participated in the chronic cohort of the Phase 1b/2a CONNECT SCI Study and meet specific eligibility criteria. Click here for further information on Expanded Access to NVG-291.

The Future of Neurorepair Has Begun. Be Part of What Comes Next.

CONTACT US